Influenza vaccine as prevention for cardiovascular diseases: Possible molecular mechanism

Vaccine

Volumn 32, Issue 48, 2014, Pages 6569-6575

  Veljkovic, Veljko ^a   Glisic, Sanja ^a   Veljkovic, Nevena ^a   Bojic, Tijana ^a   Dietrich, Ursula ^b   Perovic, Vladimir R ^a   Colombatti, Alfonso ^c  

^a UNIVERSITY OF BELGRADE   (Serbia)

^b INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

^c CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

Author keywords

Bradykinin 2 receptor; Cardio vascular diseases; Hemagglutinin; Influenza vaccine; Protein protein interaction

Indexed keywords

BRADYKININ B2 RECEPTOR; INFLUENZA VACCINE; VIRUS ANTIBODY;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; CARDIOVASCULAR DISEASE; DRUG MECHANISM; HEART PROTECTION; IMMUNOPHARMACOLOGY; INFLUENZA VACCINATION; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; NONHUMAN; PRIMARY PREVENTION; PROTEIN PROTEIN INTERACTION; SECONDARY PREVENTION; SIGNAL TRANSDUCTION; CARDIOVASCULAR DISEASES; HUMAN; INFLUENZA A VIRUS (H1N1); INFLUENZA A VIRUS (H3N2); METABOLISM; PROTEIN ANALYSIS;

ANTIBODIES, VIRAL; CARDIOVASCULAR DISEASES; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H3N2 SUBTYPE; INFLUENZA VACCINES; PROTEIN INTERACTION MAPPING; RECEPTOR, BRADYKININ B2; SIGNAL TRANSDUCTION;

EID: 84908616634     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.007     Document Type: Article

References (60)

1. http://www.who.int/mediacentre/factsheets/fs317/en/index.html.
2. Collins S.D. Excess mortality from causes other than influenza and pneumonia during influenza epidemic. Public Health Rep 1932, 47:2159-2179.
3. Pesonen E., Siitonen O. Acute myocardial infarction precipitated by infectious diseases. Am Heart J 1981, 101:512-513.
4. Tiller H.E., Smith J.W.G., Gooch C.D. Excess deaths attributable to influenza in England and Wales: age at deaths and certified cause. Int J Epideminol 1983, 12:344-352.
5. Gurfinkel E.P., Leon de la Fuente R.L., Mendiz O., Mauter B. Influenza vaccination pilot study in acute coronary syndromes and planned percutaneous coronary interventions. Circulation 2002, 105:2143-2147.
6. Nichol K.L., Nordin J., Mullooly J., Lask R., Fillbrandt K., Iwane M. Influenza vaccination and reduction of hospitalization for cardiac diseases and stroke among the elderly. N Engl J Med 2003, 348:1322-1332.
7. Gurfinkel E.P., Leon de la Fuente R.L. Two-year follow-up of the FLU vaccination acute coronary syndromes (FLUVACS) registry. Tex Heart Inst J 2004, 31:28-32.
8. Gurfinkel E.P., Leon de la Fuente R.L., Mendiz O., Mautner B. Flu vaccination in acute coronary syndromes and planned percutanous interventions (FLUVACS) study. Eur Heart J 2004, 25:25-31.
9. Davis M.M., Taubert K., Benin A.L., Brown D.W., Menasah M., Baddour G.A., Dunbar L.M.S.S., Krumholz H.M. Influenza vaccination as secondary prevention for cardiovascular diseases. Circulation 2006, 114:1549-1553.
10. Ciszewski A., Bilinska Z.T., Brydak L.B., Kepka C., Kruk M., Romanowska M., Ksiezycka E., Przyluski J., Piotrowski W., Maczynska R., Ruzyllo W. Influenza vaccination in secondary prevention from coronary ischaemic events in coronary artery diseases: FLUCAD study. Eur Heart J 2008, 29:1350-1358.
11. Phromminticul A., Kuanprasert S., Wongcharoen W., Kanjanavanit R., Chaiwarith R., Sukonthasarn A. Influenza vaccination reduces cardiovascular events in patients with acute coronary syndrome. Eur Heart J 2011, 10.1093/eurheart/ehr004.
12. Loomba R.S., Aggarwal S., Shah P.H., Arora R.R. Influenza vaccination and cardiovascular morbidity and mortality: analysis of 292383 patients. J Cardiovasc Pharm Ther 2012, 17:277-283.
13. Udell J.A., Farkouh M.E., Bhatt D.L., Cannon C.P. Influenza vaccination and reduction of cardiovascular events-a systematic review and meta-analysis. Can J Cardiol 2012, 28:S161-S162.
14. Johnstone J., Loeb M., Teo K.K., Gao P., Dyal L., Liu L., Avezum A., Cardona-Munoz E., Sleight P., Fagard R., Yusuf S. Influenza vaccination and major adverse vascular events in high-risk patients. Circulation 2012, 126:278-286.
15. Phromminticul A., Wongcharoen W. Examining the potential of the influenza vaccine for secondary prevention: a myocardial infarction vaccine?. Future Cardiol 2012, 8:345-348.
16. Bermudez-Fajardo A., Oviedo-Orta E. Influenza vaccination promotes stable atherosclerotic plaques in apoE knockout mice. Atherosclerosis 2011, 217:97-105.
17. Goeijenbier M., van Wissen M., van de Weg C., Jong E., Gerdes V.E., Meijers J.C., et al. Viral infections and mechanisms of thrombosis and bleeding. J Med Virol 2012, 84:1680-1696.
18. Udell J.A., Zawi R., Bhatt D.L., Keshtkar-Jahromi M., Gaughran F., Phrommintikul A., et al. Association between influenza vaccination and cardiovascular outcomes in high-risk patients: a meta-analysis. JAMA 2013, 310:1711-1720.
19. Osterhaus A., Fouchier R., Rimmelzwaan G. Towards universal influenza vaccines?. Philos Trans R Soc London B Biol Sci 2011, 366:2766-2773.
20. Pothlichet J., Meunier I., Davis B.K., Ting J.P., Skamene E., von Messling V., Vidal S.M. Type I IFN triggers RIG-I/TLR3/NLRP3-dependent inflammasome activation in influenza A virus infected cells. PLoS Pathog 2013, 9:e1003256.
21. Abdelwhab E.M., Veits J., Mettenleiter T.C. Avian influenza virus NS1: a small protein with diverse and versatile functions. Virulence 2013, 4:583-588.
22. Mok C.K., Lee H.H., Lestra M., Nicholls J.M., Chan M.C., Sia S.F., Zhu H., Poon L.L., Guan Y., Peiris J.S. Amino acid substitutions in polymerase basic protein 2 gene contribute to the pathogenicity of the novel A/H7N9 influenza virus in mammalian hosts. J Virol 2014, 88:3568-3576.
23. Kim I.H., Choi J.G., Lee Y.J., Kwon H.J., Kim J.H. Effects of different polymerases of avian influenza viruses on the growth and pathogenicity of A/Puerto Rico/8/1934 (H1N1)-derived reassorted viruses. Vet Microbiol 2014, 168:41-49.
24. Veljkovic N., Glisic S., Prljic J., Perovic V., Botta M., Veljkovic V. Discovery of new therapeutic targets by the informational spectrum method. Curr Protein Pept Sci 2008, 9:493-506.
25. Nwanko N., Seker H. Digital signal processing techniques: calculating biological functionalities. J Proteomics Bioinf. 2011, 4:260-268.
26. Veljkovic V., Slavic I. Simple general-model pseudopotential. Phys Rev Lett 1972, 29:105-107.
27. Veljkovic V. The dependence of the Fermi energy on the atomic number. Phys Lett A 1973, 45:41-42.
28. Veljkovic V. A theoretical approach to preselection of carcinogens and chemical carcinpgenesis 1980, Gordon & Breach, New York, NY.
29. Severson J.J., Richards K.R., Moran J.J., Hayney M.S. Persistence of influenza vaccine-induced antibody in lung transplant patients and healthy individuals beyond the season. Hum Vaccines Immunother 2012, 8:1850-1853.
30. Walsh j, Burch G.E., WhiteA, Mogabgab W., Dietlein L. A study of the effects of type A (Asian strain) influenza on the cardiovascular system of man. Ann Intern Med 1958, 49:502-528.
31. Burch G.E., Walsh J.J., Mogabgab W. A study of the response of the cardiovascular system to Asian influenza. Am Rev Respir Dis 1961, 83(2):68-78. (Pt 2).
32. Verel D., Warrack A.J., Potter C.W., Ward C., Rickards D.F. Observations on the A2 England influenza epidemic: a clinicopathological study. Am Hearth J 1976, 92:290-296.
33. Bainton D., Jones G.R., Hole D. Influenza and ischaemic heart disease-a possible trigger for acute myocardial infarction?. Int J Epidemiol 1978, 7:231-239.
34. Johansson B.E., Moran T.M., Kilbourne E.D. Antigen-presenting B cells and helper T cells cooperatively mediate intravirionic antigenic competition between influenza A virus surface glycoproteins. Proc Nat Acad Sci USA 1987, 84:6869-6873.
35. Kilbourne E.D. Comparative efficacy of neuraminidase specific and conventional influenza virus vaccines in induction of antibody to neuraminidase in humans. J Infect Dis 1976, 134:384-394.
36. Veljkovic V., Veljkovic N., Muller C.P., Müller S., Glisic S., Perovic V., Köhler H. Characterization of conserved properties of hemagglutinin of H5N1 and human influenza viruses: possible consequences for therapy and infection control. BMC Struct Biol 2009, 9:21-30.
37. Veljkovic V., Veljkovic V., Niman H.L., Glisic S., Veljkovic N., Perovic V., Muller C.P. Identification of hemagglutinin structural domain and polymorphisms which may modulate swine H1N1 interactions with human receptor. BMC Struct Biol 2009, 9:62-72.
38. Vergara-Alert J., Argilaguet J.M., Busquets N., Ballester M., Martín-Valls G.E., Rivas R., López-Soria S., Solanes D., Majó N., Segalés J., Veljkovic V., Rodríguez F., Darji A. Conserved synthetic peptides from the hemagglutinin of influenza viruses induce broad humoral and T-cell responses in a pig model. PLoS One 2012, 7:e40524.
39. Krsmanovic V., Biquard J., Sikorska-Walker M., Cosic I., Desgranges C., Trabaud M., Whitfield J., Durkin J., Achour A., Hearn M: Investigation into crossreactivity of rabbit antibodies raised against nonhomologous pairs of synthetic peptides derived from HIV-1gp120 proteins. J Pept Res 1988, 52:410-420.
40. Veljkovic V., Metlas R., Vojvodic D., Cavor Lj., Pejinovic N., Dujic A., Zakhariev S., Guarnaccia C., Pongor S. Natural autoantibodies cross-react with a peptide derived from the second conserved region of HIV-1 envelope glycoprotein gp120. Biochem Biophys Res Commun 1993, 196:1019-1024.
41. Veljkovic N., Branch D.R., Metlas R., Prljic J., Vlahovicek K., Pongor S., Veljkovic V. Design of peptide mimetics of HIV-1 gp120 for prevention and therapy of HIV disease. J Pept Res 2003, 62:158-166.
42. Veljkovic N., Branch D.R., Metlas R., Prljic J., Manfredi R., Stringer W.W., Veljkovic V. Antibodies reactive with C-terminus of the second conserved region of HIV-1gp120 as possible prognostic marker and therapeutic agent for HIV disease. J Clin Virol 2004, 31(Suppl 1):S39-S44.
43. Muscari C., Bonafe F., Giordano E., Tantini B., Fattori M., Guarnieri C., Caldarera C.M. Early preconditioning prevents the loss of endothelial nitric oxide synthase and enhances its activity in the ischemic/reperfused rat heart. Life Sci 2004, 74:1127-1137.
44. Xuan Y.T., Guo Y., Zhu Y., Wang O.I., Rokosh G., Bolli R. Endothelial nitric oxidesynthase plays an obligatory role in the late phase of ischemic preconditioning by activating the protein kinase C epsilon p44/42 mitogen-activated protein kinase pSer-signal transducers and activates transcription 1/3 pathway. Circulation 2007, 116:5350544.
45. Hausenloy D.J., Yelon D.M. Survival kinases in ischemic preconditioning and postconditioning. Cardiovasc Res 2006, 70:240-253.
46. Hausenloy D.J., Yelon D.M. Reperfusion injury salvage kinase signaling: taking a risk for cardioprotection. Heart Fail Rev 2007, 12:217-234.
47. Li X.D., Cheng Y.T., Yang Y.Jm., Meng X.M., Zhao J.L., Zhang H.T., Wu Y.J., You S.J., Wu Y.L. PKA-mediated eNOS phosphorylation in the protection of ischemic preconditioning against no-reflow. Microvasc Res 2012, 84:44-54.
48. Ju H., Venema V.J., Marrero M.B., Venema R.C. Inhibitory interactions of the bradykinin B2 receptor with endothelial nitric-oxide synthase. J Biol Chem 1998, 273:24025-24029.
49. Golser R., Gorren A.C., Leber A., Andrew P., Habisch H.J., Werner E.R., Schmidt K., Venema R.C., Mayer B. Interaction of endothelial and neuronal nitric-oxide synthases with the bradykinin B2 receptor Binding of an inhibitory peptide to the oxygenase domain blocks uncoupled NADPH oxidation. J Biol Chem 2000, 275:5291-5296.
50. Sharma J.N., Al-Sherif G.J. Pharmacological targets and prototype therapeutics in the kallikrein-kinin systems: bradykinin receptor agonists and antagonists. Sci World J 2006, 6:1247-1261.
51. Chao J., Chao L. Kallikrein-kinin in stroke, cardiovascular and renal diseases. Exp Physiol 2004, 291-298.
52. Alla S.A., Quitterer U., Grigoriev S., Maidhof A., Haasemann M., Jarnagin K., Muller-Ester W. Extracellular domains of the bradykinin B2 receptor involved in ligand binding and agonist sensing defined by anti-peptide antibodies. J Biol Chem 1996, 271:1748-1755.
53. Williams M., Matthew L. Anti-bradykinin B2 receptor BKB2R monoclonal antibody. WIPO patent application WO/2012/075342 2012, Available at http://www.freepatentsonline.com/WO2012075342A3.html.
54. Thomas P.S., Cliford N.G., Elsing M., Yates D.H. Influenza vaccination: challenges in exhalated nitric oxide levels and sputum cytology. Respirology 1999, 4:355-358.
55. Mashir A., Paschke K.M., van Duin D., Shrestha N.K., Laskowski D., Storer M.K., Yen-Lieberman B., Gordon S.M., Aytekin M., Dweik R.A. Effect of influenza A (H1N1) live attenuated intranasal vaccine on nitric oxide (FENO) and other volatiles in exhalated breath. J Breath Res 2011, 10.1088/1752-7155/5/3/037107.
56. Murphy A.V., Platts-Mills T.A.E., Lobo M., Hayden F. Respiratory nitric oxide levels in experimental human influenza. Chest 1998, 114:452-456.
57. Vrints H., Shivalkar B., Hilde H., Vanderveken O.M., Hamans E., Van de Heyning P., De Backer W., Verbraecken J. Cardiovascular mechanisms and consequences of obstructive sleep apnoea. Acta Clin Belg 2013, 68:169-178.
58. Tobaldini E., Nobili L., Strada S., Casali K.R., Braghiroli A., Montano N. Heart rate variability in normal and pathological sleep. Front Physiol 2013, 4:294.
59. Thongboonkerd V., Gozal E., Sachleben L.R., Arthur J.M., Pierce W.M., Cai J., Chao J., Bader M., Pesquero J.B., Gozal D., Klein J.B. Proteomic analysis reveals alterations in the renal kallikrein pathway during hypoxia-induced hypertension. J Biol Chem 2002, 277(38):34708-34716.
60. Duchna H.W., Guilleminault C., Stoohs R.A., Faul J.L., Moreno H., Hoffman B.B., Blaschke T.F. Vascular reactivity in obstructive sleep apnea syndrome. Am J Respir Crit Care Med 2000, 161(1):187-191.